6-alkyl-
Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
1. A compound having a structure represented by a formula:
wherein A is CR 2 or N;
wherein R 1 is selected from methyl and ethyl;
wherein R 2 , when present, is selected from hydrogen, halogen, CN, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 polyhaloalkyl, and C3 cycloalkyl;
wherein R 3 is selected from hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 polyhaloalkyl, and C3 cycloalkyl;
wherein each of R 4 , R 5 , and R 6 is independently selected from hydrogen, halogen, CN, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 polyhaloalkyl, and C3 cycloalkyl;
or a pharmaceutically acceptable salt thereof,
wherein the compound exhibits partial or total inhibition of mGluR5 response to glutamate as a decrease in response to non-maximal concentrations of glutamate in human embryonic kidney cells transfected with rat mGluR5 in the presence of the compound, compared to the response to glutamate in the absence of the compound.
2. The compound of claim 1 , wherein A is CR 2 .
3. The compound of claim 2 , wherein R 2 is selected from hydrogen, CN, halogen, and methyl.
4. The compound of claim 1 , wherein A is N.
5. The compound of claim 1 , wherein R 3 is selected from hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, and C1-C3 polyhaloalkyl.
6. The compound of claim 1 , having a structure represented by a formula:
7. The compound of claim 1 , having a structure represented by a formula:
8. A method for the treatment of a neurological and/or psychiatric disorder disorder associated with metabotropic glutamate receptor activity in a mammal comprising the step of administering to the mammal a therapeutically effective amount of a compound having a structure represented by a formula:
wherein A is CR 2 or N;
wherein R 1 is selected from methyl and ethyl;
wherein R 2 , when present, is selected from hydrogen, halogen, CN, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 polyhaloalkyl, and C3 cycloalkyl;
wherein R 3 is selected from hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 polyhaloalkyl, and C3 cycloalkyl;
wherein each of R 4 , R 5 , and R 6 is independently selected from hydrogen, halogen, CN, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 polyhaloalkyl, and C3 cycloalkyl;
or a pharmaceutically acceptable salt thereof; and
wherein the neurological and/or psychiatric disorder is selected from addiction, Alzheimer's disease, anxiety, autism spectrum disorders, depression, fragile X syndrome, and Parkinson's disease.